Summary The ability of the anti-oestrogens tamoxifen, toremifene and their 4-hydroxy and N-desmethyl metabolites to modify doxorubicin (dox) toxicity to intrinsically resistant and multidrug resistant cell lines was compared, using human breast and lung cancer, and Chinese hamster ovary cell lines. The anti-oestrogens significantly enhanced dox toxicity to multidrug resistant, P-glycoprotein-positive cell lines, but did not affect toxicity to intrinsically resistant, P-glycoprotein-negative cells. Modification was observed at clinically achievable anti-oestrogen concentrations. Toremifene and tamoxifen would therefore appear to be good candidates for in vivo studies as MDR modulating agents in selected patients with P-glycoprotein-positive tumours.
Doxorubicin (dox) is cytotoxic to many solid tumours and anthracyclines are the most active single agents available for the treatment of advanced breast cancer, with response rates of 43% in previously untreated and 28% in previously treated patients (Tormey, 1975) . Unfortunately, chemotherapy is not curative in these patients, and the development of drug resistance is a major problem in clinical management. Tumour cells may become resistant not only to the drug to which they were initially exposed, but also to a range of structurally and functionally unrelated compounds. This phenomenon, known as multidrug resistance (MDR), frequently coincides with expression of a 170kDa membrane glycoprotein (the mdrl gene product, P-glycoprotein; Endicott & Ling, 1989) . Increased levels of P-glycoprotein (Pgp), associated with resistance to dox and vinblastine, have been detected in a number of human tumours, including breast cancers in patients previously treated with chemotherapeutic drugs (Sanfilippo et al., 1991) . MDR-positive cells generally accumulate less drug than their sensitive counterparts (Kessel, 1986; Foster et al., 1988) , and the structure of Pgp indicates it may act as an ATP-dependent 'drug efflux pump', reducing intracellular drug concentrations to sub-lethal levels. The mdrl gene product has also recently been shown to be 'associated' with a volume-activated chloride channel (Valverde et al., 1992) , and is a member of the ABC (ATP binding cassette) superfamily of ATP-dependent active transporters of which over 40 members have so far been characterised (Higgins, 1989) . The superfamily includes bacterial transport proteins and the cystic fibrosis transmembrane conductance regulator, CFTR (Higgins & Hyde, 1991) . Cells expressing the MDR phenotype are typically cross-resistant to large lipophilic 'natural product' cytotoxins such as dox and the Vinca-alkaloids, but not to anti-metabolites or alkylating agents.
Circumvention of MDR could be of great clinical benefit, and many potential resistance modifiers have been evaluated. The calcium channel blocker verapamil was the first to be identified and was shown to enhance vincristine toxicity to MDR-positive P388 leukaemia (Tsuruo et al., 1981) . A photo-affinity analogue of verapamil with no calcium channel antagonist activity binds Pgp (Qian & Beck, 1990) , indicating that the MDR-modulating activity of verapamil is due to competitive inhibition of Pgp at specific drug binding sites, resulting in inhibition of drug efflux (Kessel, 1986 , 1984; Kessel, 1986) , although the increases in drug concentration observed rarely exceed 2-to 3-fold and may not be sufficient to explain the large enhancements of drug toxicity demonstrated (Fairchild & Cowan, 1991 Twentyman et al., 1987) and the anti-oestrogens tamoxifen (Ramu et al., 1984) and toremifene (DeGregorio et al., 1989) .
Tamoxifen and toremifene are used to treat breast cancer, and their ability to bind oestrogen receptors (ER) is well documented (Lerner & Jordan, 1990; Kangas, 1990) . Both anti-oestrogens are well tolerated, although toremifene can be administered at higher doses (Kohler et al., 1990; Robinson et al., 1990) , and higher plasma concentrations can therefore be achieved (DeGregorio et al., 1989; Kaye, 1990) . Tamoxifen and toremifene are metabolised extensively in vivo, primarily to the N-desmethyl, N-didesmethyl and 4-hydroxy derivatives (Jordan et al., 1983) ; Kangas, 1990; Kaye, 1990; Robinson et al., 1991) . These metabolites differ from their parent compounds in their biological activity; for example, 4-hydroxy tamoxifen (OHTx) has 100-fold greater affinity for ER than tamoxifen (Jordan et al., 1980) . The cytotoxic and MDR-modulating activity of tamoxifen, toremifene and their major metabolites should therefore be thoroughly investigated if these compounds are to be seriously considered as potential in vivo modifiers of MDR.
The effects of tamoxifen, toremifene and their two major metabolites on cell growth and on dox toxicity have been studied. The panel of cell lines used includes three Pgppositive MDR cell lines and their drug-sensitive parental lines (Table I ). In addition, a range of human breast and lung cancer cell lines of varying histological type were included in this study. They differ markedly in intrinsic sensitivity to dox, and this effect is unrelated to P-glycoprotein expression.
Materials and methods

Cell lines and tissue culture
Wild type cell lines and their drug-resistant sublines used in this study were (i) the human non-small cell lung carcinoma S1 (Baas et al., 1990) and its mdrl-transfected subline S1/1.1 which has mdrl levels at least 100-fold higher than the wild (Batist et al., 1986) and (iii) the Chinese hamster ovary cell line CHO-KI (Puck et al., 1958) and its dox resistant sub-line CHO-KIAdr (Chatterjee & Harris, 1990 Cells were incubated continuously with drug and/or modifier at 37°C (5% C02, 100% humidity) for 4 days. Cytotoxicity was determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] assay (Mosmann, 1983; Carmichael et al., 1987) . MTT (50 jil, 2 mg ml-') was aliquoted into all wells and the cells incubated for a further 4 h. Plates were inverted to discard medium and formazan crystals solubilised in 100y1 DMSO with 25 gl glycine buffer (0.1 M glycine in 0.1 M NaCl, pH 10.5; Plumb et al., 1989) . Plates were agitated for 5 min, and optical densities determined immediately at 540 nm using a Titertek Multiskan Plus MKII ELISA plate reader. Data were analysed using Deltasoft Elisa Analysis software (BioMetallics Inc., Princeton, NJ).
Cytotoxicity was expressed as the IC50 value; the concentration of drug causing a 50% reduction of control cell optical density. ICm values are presented as the mean of those determined from at least six experiments ± the standard error of the mean (s.e.m.). The number of repeats is indicated in the Table and Figure legends . IC50 values determined in the presence and absence of anti-oestrogens were compared using paired t-tests. Modification of dox toxicity by anti-oestrogens was expressed as a modification factor (MF), calculated by dividing the dox IC50 value determined in the absence of anti-oestrogen by that determined in the presence of anti-oestrogen. A MF value of 1 therefore indicates that anti-oestrogens do not affect dox toxicity, while values greater than 1 indicate enhancement of, and values less than 1 protection from, dox toxicity. Immunocytochemical staining Cells in exponential growth phase were removed from flasks by trypsinisation, washed three times with PBS and resuspended in PBS to a density of 105 cells ml-'. Cell suspension (0.5 ml) was applied to microscope slides by cytospinning. Cells were incubated first with a monoclonal antibody (MRK16 or C219) for 30 min, then with peroxidase-conjugated rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). The peroxidase reaction was developed using diaminobenzidine (Sigma Chemical Co.) and hydrogen peroxide.
Results
Cell lines were stained with monoclonal antibodies, MRK16 and C219, which recognise different epitopes of Pgp. In general, similar results were obtained with both antibodies, although MRK16 stained cells more strongly (Table I) Table I. Tamoxifen and its structural analogue toremifene were equitoxic (Table II) . The metabolites of these anti-oestrogens had similar toxicities to their parent compounds (data not shown), although their reported affinities for ER vary (Jordan et al., 1980) . ER-positive MCF-7 cells were most sensitive to anti-oestrogens, exhibiting biphasic dose response curves, while ER-negative cell lines were in general more resistant, with steep, monophasic dose response curves (data not shown). Although the MCF-7Adr cell line was more resistant to anti-oestrogens than its ER-positive parental line, the remaining MDR-positive cell lines were not, indicating that such resistance is not part of the MDR phenotype.
MCF-7Adr cells were 180-fold resistant to dox relative to wild type MCF-7 cells (Table III) . (Table   II) wild type MCF-7 cells overlayed, indicating that tamoxifen had no effect on drug toxicity. However, it should be noted that the MNC of anti-oestrogens for MCF-7 was 1 pm, a dose causing no significant modification of dox toxicity to either cell line. (Figure 3 , Table IV ).
The effects of anti-oestrogens on dox toxicity to Pgpnegative cell lines were further investigated by determining dox toxicity to 6 MDR-negative lung and breast cancer cell lines; lCm values ranging from 22 to 335 nm were deter- (5 and 10 t4M) on drug sensitivity was investigated (Table IV) .
Dox toxicity in the presence and absence of anti-oestrogens was not significantly different, indicating that no modification of drug toxicity was achieved.
Discussion
Despite their different affinities for ER, tamoxifen, toremifene and their metabolites were equitoxic to a range of breast and lung cancer cell lines. This results differs from that described by DeGregorio et al. (1989), who found MCF-7Adr cells to be more sensitive to OHTx and NdMTx than to tamoxifen. Cytotoxicity was assessed using methylene blue staining after 48 h exposure to anti-oestrogens. Differences between their results and those presented here may arise from different assay systems employed. Tamoxifen, toremifene and their metabolites are structurally similar, and it is perhaps not surprising that toxicity to ER-negative cells does not vary greatly between these compounds. Higher resistance of MCF-7Adr cells to anti-oestrogens relative to wild type MCF-7 cells was probably due to different ER status rather than mdrl expression; CHO-KI and CHO-KlAdr cells were equally sensitive to anti-oestrogens, as were Sl and Si/1.1 cells. Resistance to anti-oestrogens therefore does not appear to be characteristic of the MDR phenotype, consistent with the report by Kessel (1986) that tamoxifen is not transported by Pgp. Tamoxifen and toremifene substantially modified dox toxicity to Pgp-positive CHO-K1Adr and MCF-7Adr cells. Modification of dox toxicity by anti-oestrogens occurred irrespective of ER status and was unaffected by oestradiol (unpublished data), indicating that enhanced dox toxicity is not an anti-oestrogenic effect. In fact, substantial modification of drug toxicity is more likely to be observed with ER-negative cell lines which can tolerate higher doses of anti-oestrogens, because MDR-modification occurs in a dose dependent manner (Figure 2) .
No enhancement of dox toxicity to MDR-negative lung and breast cancer cell lines exhibiting a 15-fold range of sensitivities to the drug was observed and modification of drug toxicity by anti-oestrogens would therefore appear to be an MDR-specific effect. However, dox toxicity to CHO-KI cells was enhanced. Gupta (1988) demonstrated that wild type CHO cells display intrinsic resistance to drugs associated with MDR, which can be reversed by verapamil. CHO-Kl cells stained weakly with anti-Pgp antibodies (Table I) , and intrinsic MDR in CHO cells may therefore be mediated by Pgp. This is supported by the discovery that Pgp is associated with a volume-activated chloride channel (Valverde et al., 1992) , as CHO cells are known to respond to increases in volume with enhanced chloride channel activity (Sarkadi et al., 1984) .
The ability of tamoxifen, toremifene and their metabolites to modify dox resistance in MCF-7Adr cells was compared.
Maximal modification of MDR was observed at 10-20tM. The relative ranking of efficacy for both tamoxifen and toremifene appeared to be: hydroxy metabolites> parent compounds> N-desmethyl metabolites. DeGregorio et al. (1989) also observed modulation of dox toxicity to MCF-7Adr cells by toremifene and its metabolites, but found OHTf to be less effective than toremifene and NdMTf. Differences between their results and those presented here may arise from differences between experimental procedures. DeGregorio and co-workers described synergy between toxic concentrations of anti-oestrogens and a single (toxic) dose of dox (1 uM), whilst in the present study, the effects of non-toxic doses of anti-oestrogens on a range of dox concentrations were determined. The ability of anti-oestrogen metabolites to reverse drug resistance is highly significant as these compounds are major products of tamoxifen and toremifene metabolism. Steady state serum levels of N-desmethyl and 4-hydroxy metabolites are, respectively, -140% and -33% parent compound levels in patients receiving tamoxifen (Lien et al., 1989 ) and '400% and -25% in patients treated with toremifene (DeGregorio et al., 1989; Kohler et al., 1990) .
Overexpression of Pgp is generally associated with decreased intracellular drug concentration, and there is evidence that anti-oestrogens increase drug accumulation in MDR-positive cells (Kessel, 1986; Ramu et al., 1984 (Berman et al., 1991) . The mechanism by which anti-oestrogens alter cellular drug retention is not fully understood. Tamoxifen inhibits protein kinase C (PKC) (O'Brian et al., 1985; Su et al., 1985; Horgan et al., 1986) , an enzyme implicated in the phosphorylation and concomitant activation of Pgp (Chambers et al., 1990 ). Inhibition of PKC by staurosporine reduces Pgp phosphorylation, increases daunorubicin accumulation and enhances drug toxicity in MDR-positive HL-60 cells (Ma et al., 1991) . Staurosporine also increases vincristine accumulation in MDR-positive human myelogenous leukaemia (K562/ADM) cells (Sato et al., 1990) . Tamoxifen may therefore modulate MDR through inhibition of PKC, leading to inactivation of Pgp and enhanced drug accumulation. However, while
NdMTx is the most active inhibitor of PKC (O'Brian et al., 1988) it is the least effective modifier of MDR in the present study.
Tamoxifen is also a calmodulin antagonist (Lam, 1984) and it has been suggested that this activity may be responsible for modulation of MDR (Chatterjee & Harris, 1990 Interestingly, dox was equally toxic to the non-small cell lung carcinoma cell lines S1 and S1/1.1, although the mdrltransfected cells were shown to be Pgp-positive with antibody staining (Table I) . The low levels of resistance in S1/1.1 cells described in this study are typical of some mdrl transfectants, and occur despite elevated levels of Pgp expression. Fairchild et al. (1990) transfected wild type MCF-7 cells with the mdrl gene isolated from its MDR-positive subline, MCF7Adr and achieved levels of Pgp in transfectants equal to, or exceeding, those observed in MCF-7Adr cells. However, although the same pattern of MDR was displayed, the transfected cells did not exhibit the high degree of resistance observed in MCF-7Adr cells. It therefore appears that while expression of mdrl can confer the MDR phenotype, it is not sufficient to generate the very high levels of resistance observed in cell lines which have been exposed to high drug concentrations in vitro. The possible interaction between PKC and Pgp has been discussed above. PKC levels are frequently elevated in highly resistant MDR-positive cells (Fine et al., 1988) and may be necessary for activation of Pgp and expression of the full MDR phenotype.
It is also apparent that chronic drug-treatment activates multiple, independent mechanisms of resistance. Dox exerts multiple cellular effects, including topoisomerase II inhibition (Tewey et al., 1984) , DNA binding (Neidle, 1979) , membrane disruption (Tritton, 1991) and production of oxygen radicals (Bachur et al., 1979) , and may induce resistance via any of these pathways.
Patients treated with tamoxifen or toremifene accumulate stable serum concentrations of parent compounds and metabolites (Kohler et al., 1990; Langan-Fahey et al., 1990) . Patients receiving 'high dose' tamoxifen therapy (480 mg/day, Stuart et al., 1992) achieved plasma tamoxifen levels of 3.5 JIM, while total levels of tamoxifen and metabolites were -7 tLM. Although anti-oestrogens have been demonstrated to be -99% bound to plasma proteins such as alpha, acid glycoprotein (Chatterjee & Harris, 1990) , these compounds are lipophilic cations and it is therefore likely that they accumulate to higher concentrations within the cell. Lien et al., (1991) determined anti-oestrogen levels in patients treated with 20-80 mg tamoxifen daily. A mean serum tamoxifen concentration of 0.2 fLM was achieved; however, mean levels in brain were 4.5 ttM and in metastases, 6.6 JiM. The same trend was observed with NdMTx and OHTx, and on average the concentration of anti-oestrogen accumulated in tissues was 16-to 30-fold higher than in serum. The total concentration of tamoxifen, OHTx and NdMTx achieved in metastases was -16 gM, a concentration of anti-oestrogen which would enhance dox toxicity to MCF-7Adr cells -7-fold in vitro. This result suggests that 'low dose' therapy may generate antioestrogen levels sufficient to modulate MDR in vivo. Alternatively, if the same degree of compartmentalisation between serum and tissues occurs during high dose tamoxifen treatment, very high intracellular anti-oestrogen concentrations may be reached, and significant enhancement of cytotoxic drug action could be achieved. Tamoxifen, toremifene and their 4-hydroxy and Ndesmethyl metabolites are effective in vitro modifiers of MDR at achievable serum concentrations. They are clinically welltolerated and may therefore be of great benefit in the treatment of tumours which characteristically express high levels of Pgp, such as renal, colorectal and adrenal carcinomas. However, it should be stressed that little effect was observed in intrinsically resistant MDR-negative cell lines, making patient selection an important parameter in the clinical evaluation of this class of modifier.
